Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07202546) titled 'A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naive Persons With HIV-1 (INNOVATE Study)' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: ViiV Healthcare
Condition:
HIV Infections
Intervention:
Drug: VH4524184
Drug: Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 28, 2025
Target Sample Size: 550
To know more, visit http...